Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer
- PMID: 18563785
- DOI: 10.1002/bjs.6136
Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer
Abstract
Background: Early detection of colorectal cancer could reduce cancer-specific mortality. The aim of this trial was to evaluate the effect of faecal occult blood test (FOBT) screening on colorectal cancer mortality in a Swedish population.
Methods: All 68,308 citizens in Göteborg born between 1918 and 1931 were randomized to a screening or a control group at the age of 60-64 years. All were screened two to three times with rehydrated Hemoccult-II. Compliance was 70.0 per cent (23,916 individuals). Those with a positive test result were offered sigmoidoscopy and a double-contrast enema. The primary endpoint was death from colorectal cancer.
Results: After a mean of 9 years from the last screening, there was a significant reduction in colorectal cancer mortality in the screening group compared with the control group. The overall risk ratio of death from colorectal cancer was 0.84 (95 per cent confidence interval 0.71 to 0.99). The groups did not differ in incidence of colorectal cancer or in overall mortality.
Conclusion: FOBT screening significantly reduces colorectal cancer mortality.
(c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Comment in
-
Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer (Br J Surg 2008; 95: 1029-1036).Br J Surg. 2008 Nov;95(11):1428-9; author reply 1429. doi: 10.1002/bjs.6425. Br J Surg. 2008. PMID: 18844282 No abstract available.
Similar articles
-
Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.J Natl Cancer Inst. 2005 Mar 2;97(5):347-57. doi: 10.1093/jnci/dji050. J Natl Cancer Inst. 2005. PMID: 15741571 Clinical Trial.
-
Early detection of colorectal cancer with faecal occult blood test screening.Br J Surg. 2010 Oct;97(10):1567-71. doi: 10.1002/bjs.7150. Br J Surg. 2010. PMID: 20603855 Clinical Trial.
-
Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.Br J Surg. 2009 May;96(5):533-40. doi: 10.1002/bjs.6568. Br J Surg. 2009. PMID: 19358181
-
[Mass screening for colorectal cancer].Rev Epidemiol Sante Publique. 1996;44 Suppl 1:S7-14. Rev Epidemiol Sante Publique. 1996. PMID: 8935859 Review. French.
-
Screening for colorectal cancer.Curr Opin Gen Surg. 1994:79-84. Curr Opin Gen Surg. 1994. PMID: 7584018 Review.
Cited by
-
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.BMC Med. 2011 Dec 14;9:133. doi: 10.1186/1741-7015-9-133. BMC Med. 2011. PMID: 22168215 Free PMC article.
-
Knowledge, attitude and practice towards early screening of colorectal cancer in Riyadh.J Family Med Prim Care. 2020 May 31;9(5):2273-2280. doi: 10.4103/jfmpc.jfmpc_290_20. eCollection 2020 May. J Family Med Prim Care. 2020. PMID: 32754487 Free PMC article.
-
Effectiveness of Colorectal Cancer (CRC) Screening on All-Cause and CRC-Specific Mortality Reduction: A Systematic Review and Meta-Analysis.Cancers (Basel). 2023 Mar 24;15(7):1948. doi: 10.3390/cancers15071948. Cancers (Basel). 2023. PMID: 37046609 Free PMC article. Review.
-
A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme.Br J Cancer. 2012 Aug 21;107(5):757-64. doi: 10.1038/bjc.2012.331. Epub 2012 Jul 31. Br J Cancer. 2012. PMID: 22850549 Free PMC article.
-
An ongoing case-control study to evaluate the NHS Bowel Cancer Screening Programme.BMC Cancer. 2014 Dec 13;14:945. doi: 10.1186/1471-2407-14-945. BMC Cancer. 2014. PMID: 25495609 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical